Latest United States News

Renegade Exploration has boosted and prolonged its loan facility to $2 million, using shares from its recent Carpentaria JV sale as additional security to support ongoing exploration.

DroneShield Limited reported record revenue of $125.8 million for the half-year ended June 2026, driven by recurring income and geographic diversification, while posting a $32.2 million statutory loss due to margin pressure and strategic investments.

Calix Limited posted a 16% revenue increase to $39.2 million in FY26 driven by strong growth in its Magnesia business, while reporting a substantial net loss of $51 million largely due to a one-off impairment. The company advanced key industrial decarbonisation projects and strengthened strategic partnerships, focusing on capital-light commercialisation.

Radiopharm Theranostics has dosed the first patient in the second cohort of its Phase 1/2a trial for RV-01, a radiopharmaceutical targeting B7-H3 expressing solid tumors, marking a key dose escalation milestone.

QEM Limited’s review of the Big It Tungsten Project in Idaho reveals significant untapped high-grade tungsten, antimony, and gold mineralisation with extensive underground workings, setting the stage for a modern exploration campaign amid strategic supply concerns.

Terragen Holdings posted a slight increase in net loss to AUD 3.75 million for FY2026, while advancing key commercial trials and securing a $7 million equity raise to fuel growth.

Genetic Signatures narrowed its FY2026 net loss by 30% to $14 million amid a strategic overhaul, signing a key 10-year supply deal with Denmark’s Hvidovre Hospital and resetting its US market approach.

OD6 Metals has recalibrated its Horseshoe fluorspar grades upward by nearly 13% following a re-assay program, confirming exceptional high-grade mineralisation near surface at its Quinn Project in Nevada.

Palisade Metals has boosted its Finley Basin Tungsten Project landholding by 87% to over 696 hectares, setting the stage for maiden drilling in Q3 2026 aimed at validating historical tungsten mineralisation in Montana.

Reece Limited posted a 4.5% revenue increase to $9.38 billion in FY26, driven by a strong ANZ recovery and tempered by ongoing challenges in the US residential market. Despite flat EBITDA and a slight dip in net profit, the company unveiled a revamped long-term executive remuneration plan aligned with its 2030 strategy.

Prescient Therapeutics cut its net loss by 4.4% to $7 million in FY26 while expanding its PTX-100 Phase 2a trial across three continents and securing key regulatory designations in Europe and the US.

Li-S Energy reported a reduced net loss of $4.9 million in FY26, propelled by major technological advances and a $7.8 million ARENA grant to scale manufacturing. The company secured key regulatory approvals and expanded strategic defence partnerships, positioning itself at the forefront of sovereign lithium sulfur battery supply.